戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 hape the genetic diversity of healthy blood (clonal hematopoiesis).
2 ion or chromosomal abnormality indicative of clonal hematopoiesis.
3 -forming unit colonies but not in those with clonal hematopoiesis.
4 eoplasms (MPN) characterized by multilineage clonal hematopoiesis.
5 polyclonal hematopoiesis and in 4 of 10 with clonal hematopoiesis.
6  identified in this subset with evidence for clonal hematopoiesis.
7 e myeloid skewing and mutations that lead to clonal hematopoiesis.
8  in myeloid malignancies and their precursor clonal hematopoiesis.
9 ts observed among genes also associated with clonal hematopoiesis.
10  most frequently mutated gene in age-related clonal hematopoiesis.
11 V600E mutation (P = .049) than those without clonal hematopoiesis.
12  were associated with DNMT3A and TET2 mutant clonal hematopoiesis.
13 sociation between cardiovascular disease and clonal hematopoiesis.
14 h identification of alterations arising from clonal hematopoiesis.
15 loid as well as lymphoid malignancies and in clonal hematopoiesis.
16 lls and demonstrate its utility for modeling clonal hematopoiesis.
17 lays an important role in the development of clonal hematopoiesis.
18 ions in genes not previously associated with clonal hematopoiesis.
19 y/mortality in individuals with age-related, clonal hematopoiesis.
20 genetic mechanism by which mutant p53 drives clonal hematopoiesis.
21 ts with cancer) had features consistent with clonal hematopoiesis.
22 2 gene in hematopoietic cell development and clonal hematopoiesis.
23 progenitor cells (HSPCs) and/or by promoting clonal hematopoiesis.
24 isorders in which recurrent mutations define clonal hematopoiesis.
25 ts with congenital neutropenia to assess for clonal hematopoiesis.
26 erved in hematological malignancies(1-3) and clonal hematopoiesis(4,5).
27                                              Clonal hematopoiesis, a common age-related phenomenon ma
28                                              Clonal hematopoiesis, a condition in which acquired soma
29                                              Clonal hematopoiesis, a condition in which individual he
30 tion not only to MPN, but also to JAK2 V617F clonal hematopoiesis, a more common phenomenon that may
31 that define myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation, peripher
32 n review the role played by mutant DNMT3A in clonal hematopoiesis, accompanied by its effect on immun
33 odysplastic syndromes and are also common in clonal hematopoiesis, acute myeloid leukemia, chronic ly
34 matopoiesis at the time of ABMT or developed clonal hematopoiesis after ABMT.
35                           In 3 patients with clonal hematopoiesis analyzed by WES, we identified a so
36 imaging to investigate the interplay between clonal hematopoiesis and atherosclerosis in a longitudin
37 re subject to frequent missense mutations in clonal hematopoiesis and diverse neoplastic diseases.
38                                              Clonal hematopoiesis and hematologic neoplasms often fea
39  (PMF) are chronic diseases characterized by clonal hematopoiesis and hyperproliferation of terminall
40  translocation methylcytosine dioxygenase 2) clonal hematopoiesis and hypertension.
41 lore recent advances in the understanding of clonal hematopoiesis and its role in heart failure, emph
42 equencing data uncovers correlations between clonal hematopoiesis and lung cancer risk factors, ident
43 s and have a propensity for the evolution to clonal hematopoiesis and malignancy.
44 omising way to model the complex genetics of clonal hematopoiesis and myeloid disorders using CRISPR-
45 deficient mice to generate genetic models of clonal hematopoiesis and neoplasia.
46                                DNMT3A-driven clonal hematopoiesis and, subsequently, periodontitis we
47 r disease-modifying drugs that can eradicate clonal hematopoiesis and/or prevent progression to more
48 re structural somatic variants indicative of clonal hematopoiesis, and are associated with aberrant l
49                              Lynch syndrome, clonal hematopoiesis, and cervical intraepithelial neopl
50  identifies genetic variants correlated with clonal hematopoiesis, and highlights hundreds of potenti
51 hematopoietic defects associated with aging, clonal hematopoiesis, and MDS.
52 ene are the most common cause of age-related clonal hematopoiesis (ARCH) in older individuals, and ar
53                                  Age-related clonal hematopoiesis (ARCH) is characterized by age-asso
54 leukemia onset in the context of age-related clonal hematopoiesis (ARCH).
55 ol, which was termed in the past age-related clonal hematopoiesis (ARCH).
56  increasing frequency with which people with clonal hematopoiesis are discovered and the need for cou
57 sions of mutated hematopoietic cells, termed clonal hematopoiesis, are common in aging humans.
58 l hematopoiesis at the time of ABMT and that clonal hematopoiesis, as detected by the HUMARA assay, i
59       Our findings support the occurrence of clonal hematopoiesis-associated mutations as a widesprea
60  Indeed, several studies have now shown that clonal hematopoiesis associates with increased risk of a
61 at a significant proportion of patients have clonal hematopoiesis at the time of ABMT and that clonal
62  skewed XIP, and 10 of 78 (13.5%) either had clonal hematopoiesis at the time of ABMT or developed cl
63                                              Clonal hematopoiesis becomes increasingly common with ag
64               These data are consistent with clonal hematopoiesis being driven by a continuing risk o
65 ve resulted in highly sensitive detection of clonal hematopoiesis beyond these known driver genes.
66 nscriptional priming of DNMT3A-mutated human clonal hematopoiesis bone marrow progenitors.
67 his context, somatic alterations can promote clonal hematopoiesis by improving the competitive fitnes
68                               Age-associated clonal hematopoiesis caused by acquired mutations in mye
69 e we study this phenomenon in the context of clonal hematopoiesis (CH) and the development of therapy
70 k factors that contribute to CHIP-associated clonal hematopoiesis (CH) are poorly understood.
71                                              Clonal hematopoiesis (CH) arises when a substantial prop
72                                              Clonal hematopoiesis (CH) arises when hematopoietic stem
73                                              Clonal hematopoiesis (CH) as a marker of cancer developm
74                                              Clonal hematopoiesis (CH) becomes more prevalent with ag
75       Chronic lymphocytic leukemia (CLL) and clonal hematopoiesis (CH) both commonly occur in elderly
76                                              Clonal hematopoiesis (CH) has been associated with a var
77                                              Clonal hematopoiesis (CH) has been associated with devel
78                                              Clonal hematopoiesis (CH) has emerged as an independent
79  the impact of germline genetic variation on clonal hematopoiesis (CH) in 731,835 individuals.
80  Recent studies identified nearly ubiquitous clonal hematopoiesis (CH) in AA patients.
81                             The discovery of clonal hematopoiesis (CH) in older individuals has chang
82 studies have reported an association between clonal hematopoiesis (CH) in the infused PBSC product an
83                                              Clonal hematopoiesis (CH) increases inflammasome-linked
84                                              Clonal hematopoiesis (CH) is a molecular biomarker assoc
85                                              Clonal hematopoiesis (CH) is a phenomenon caused by expa
86                                              Clonal hematopoiesis (CH) is a premalignant condition th
87                                  Age-related clonal hematopoiesis (CH) is a risk factor for malignanc
88                                              Clonal hematopoiesis (CH) is a risk factor for the devel
89                                              Clonal hematopoiesis (CH) is an age-related condition pr
90                                              Clonal hematopoiesis (CH) is an aging-associated conditi
91                                              Clonal hematopoiesis (CH) is an aging-related hematologi
92                                              Clonal hematopoiesis (CH) is associated with age and an
93                                              Clonal hematopoiesis (CH) is characterized by the acquis
94                                              Clonal hematopoiesis (CH) is common among older people a
95                                              Clonal hematopoiesis (CH) is common in older persons and
96                                              Clonal hematopoiesis (CH) is defined as a single hematop
97                                              Clonal hematopoiesis (CH) is defined as clonal expansion
98                                              Clonal hematopoiesis (CH) is defined as the acquisition
99                                              Clonal hematopoiesis (CH) is defined by the expansion of
100                                              Clonal hematopoiesis (CH) is described as the outsized c
101                                              Clonal hematopoiesis (CH) is detectable in upwards of 20
102 asured within the hematopoietic compartment, clonal hematopoiesis (CH) is now recognized as a common
103                                              Clonal hematopoiesis (CH) is said to occur when a substa
104 at acquired hematologic mutations leading to clonal hematopoiesis (CH) may further increase vulnerabi
105                                              Clonal hematopoiesis (CH) of indeterminate potential (CH
106                                              Clonal hematopoiesis (CH) refers to the acquisition of s
107                                              Clonal hematopoiesis (CH) results from somatic genomic a
108 t that many treated patients have persistent clonal hematopoiesis (CH) that may not reflect residual
109 hly variable, ranging from clinically silent clonal hematopoiesis (CH) to leukemic progression.
110                                              Clonal hematopoiesis (CH) was detected in 19.7% and 27.7
111                                              Clonal hematopoiesis (CH) with acquired pathogenic varia
112 etic stem cell (HSC) mutations can result in clonal hematopoiesis (CH) with heterogeneous clinical ou
113       In exploratory analyses, we considered clonal hematopoiesis (CH) with variant allele fraction (
114                         We hypothesized that clonal hematopoiesis (CH), a state in which somatic muta
115 most frequently mutated genes in age-related clonal hematopoiesis (CH), alongside DNA methyltransfera
116                                              Clonal hematopoiesis (CH), as evidenced by recurrent som
117                                              Clonal hematopoiesis (CH), the clonal expansion of a blo
118                                              Clonal hematopoiesis (CH), the expansion of hematopoieti
119                                              Clonal hematopoiesis (CH)-age-related expansion of mutat
120                                              Clonal hematopoiesis (CH)-associated genomic alterations
121 ss promote its relative expansion leading to clonal hematopoiesis (CH).
122 DNMT3A) is the most commonly mutated gene in clonal hematopoiesis (CH).
123 tionships between LOY, serum biomarkers, and clonal hematopoiesis (CH).
124 ng tissues, particularly evident in blood as clonal hematopoiesis (CH).
125 DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH).
126  donations) to investigate the phenomenon of clonal hematopoiesis (CH).
127 nd and become detectable, now referred to as clonal hematopoiesis (CH).
128 This cfDNA sequencing approach revealed that clonal hematopoiesis constitutes a pervasive biological
129                                         This clonal hematopoiesis correlates with an increased risk o
130                                     However, clonal hematopoiesis does result in the accumulation of
131                                              Clonal hematopoiesis driven by mutations of DNMT3A (DNA
132                                              Clonal hematopoiesis driven by somatic heterozygous TET2
133                                              Clonal hematopoiesis driven by somatic mutations in hema
134 phenomenon marked by expansion of cells with clonal hematopoiesis driver mutations, has been associat
135                           The acquisition of clonal hematopoiesis-driver mutations (CHDMs) occurs wit
136 zed in n=6 patients with HF harboring DNMT3A clonal hematopoiesis-driver mutations and n=4 patients w
137 es and T cells of patients with HF harboring clonal hematopoiesis-driver mutations in DNMT3A exhibit
138 ugh experimental studies suggest that DNMT3A clonal hematopoiesis-driver mutations may enhance inflam
139                                              Clonal hematopoiesis due to mutations in TP53 was presen
140                                  Conversely, clonal hematopoiesis due to mutations of CSF3R was prese
141  hematopoiesis, most individuals who acquire clonal hematopoiesis during aging will never develop MDS
142                          A predisposition to clonal hematopoiesis had an autosomal dominant pattern o
143 , establishing the causal role of smoking in clonal hematopoiesis has been limited by observational s
144                 Somatic mutations leading to clonal hematopoiesis have been described in IBMFSs, but
145 lly heterogeneous disorders characterized by clonal hematopoiesis, impaired differentiation, peripher
146 splastic lineages) from 67 patients revealed clonal hematopoiesis in 13 (50%) of 26 cases with MDS-PA
147                         We found evidence of clonal hematopoiesis in 5 of 8 studied cases based on cl
148 f TCA established the presence or absence of clonal hematopoiesis in about 90% of female subjects.
149                            We did not detect clonal hematopoiesis in any of the tested subjects.
150  HUMARA alleles, was reported as evidence of clonal hematopoiesis in approximately 30% of elderly wom
151 nality assays are suitable for evaluation of clonal hematopoiesis in elderly women.
152               This HUMARA at times indicated clonal hematopoiesis in healthy elderly women, thus prec
153 mosome genes (qTCA) and found no evidence of clonal hematopoiesis in healthy nonanemic elderly person
154   Moreover, mutations in BRCC36 are found in clonal hematopoiesis in humans.
155  understanding of the processes that promote clonal hematopoiesis in IBMFSs may inform clinical surve
156               Furthermore, we did not detect clonal hematopoiesis in more than 200 healthy nonelderly
157  age-specific enrichment, in part reflecting clonal hematopoiesis in older individuals.
158 ontinue to proliferate and expand, mimicking clonal hematopoiesis in patients postchemotherapy.
159                   Here, we unravel increased clonal hematopoiesis in patients with iWM (61% vs 23% in
160                                DNMT3A-driven clonal hematopoiesis in recipient mice promoted naturall
161  issue of Blood, Eskelund et al characterize clonal hematopoiesis in serial samples from persons with
162 been observed in AML and in individuals with clonal hematopoiesis in the absence of leukemic transfor
163 roliferative neoplasms (MPNs) and JAK2 V617F clonal hematopoiesis in the general population.
164 is sufficient to drive premature age-related clonal hematopoiesis in these inherited disorders.
165  second most commonly mutated gene linked to clonal hematopoiesis, in the hematopoietic cells of athe
166 es clinical considerations for patients with clonal hematopoiesis, including important points for hem
167 rdiovascular disease and are associated with clonal hematopoiesis, inflammation, and adverse vascular
168                                  Age-related clonal hematopoiesis is a common condition that is assoc
169  expected consequence of mutation-associated clonal hematopoiesis is an increased risk of hematologic
170                                              Clonal hematopoiesis is associated with low CD4 nadir, i
171                                              Clonal hematopoiesis is exceptionally common with human
172                                      Because clonal hematopoiesis is not deterministic of malignant t
173        The observed proportion of putatively clonal hematopoiesis is similar to the lifetime incidenc
174 al (CHIP), also referred to as aging-related clonal hematopoiesis, is defined as an asymptomatic clon
175                      This outgrowth, called "clonal hematopoiesis," is highly prevalent in the elderl
176  discuss recent advances in our knowledge of clonal hematopoiesis, its relationship to malignancies,
177 emorial Sloan Kettering (MSK) and the Korean Clonal Hematopoiesis (KoCH) consortia, we show that CH i
178 vascular event in an individual patient with clonal hematopoiesis may be low, the possibility of futu
179                                  People with clonal hematopoiesis may come to clinical attention in a
180 e germline variants of genes associated with clonal hematopoiesis may increase the likelihood that an
181 ic morphology of blood and marrow cells, and clonal hematopoiesis, most individuals who acquire clona
182                  CODEC detected genome-wide, clonal hematopoiesis mutations from single DNA molecules
183                                              Clonal hematopoiesis mutations in ECD were detected in c
184 , and highlights hundreds of potential novel clonal hematopoiesis mutations.
185 ns in TET2 occur frequently in patients with clonal hematopoiesis, myelodysplastic syndrome (MDS), an
186                                  BAX-mutated clonal hematopoiesis occurred independently of prior flu
187                                              Clonal hematopoiesis occurs normally, especially with ag
188                                              Clonal hematopoiesis of indeterminate potential (CHIP) a
189                                              Clonal hematopoiesis of indeterminate potential (CHIP) a
190                                              Clonal hematopoiesis of indeterminate potential (CHIP) a
191  mutations in the peripheral blood is termed clonal hematopoiesis of indeterminate potential (CHIP) a
192                                              Clonal hematopoiesis of indeterminate potential (CHIP) c
193                                              Clonal hematopoiesis of indeterminate potential (CHIP) c
194                                              Clonal hematopoiesis of indeterminate potential (CHIP) c
195                                              Clonal hematopoiesis of indeterminate potential (CHIP) d
196                                              Clonal hematopoiesis of indeterminate potential (CHIP) h
197                                              Clonal hematopoiesis of indeterminate potential (CHIP) h
198                                              Clonal hematopoiesis of indeterminate potential (CHIP) h
199 of somatic mutations in blood cell lineages, clonal hematopoiesis of indeterminate potential (CHIP) i
200                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
201                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
202                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
203                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
204                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
205                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
206                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
207                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
208                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
209                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
210                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
211                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
212                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
213                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
214                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
215                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
216                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
217                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
218                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
219                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
220                                              Clonal hematopoiesis of indeterminate potential (CHIP) i
221                                      Purpose Clonal hematopoiesis of indeterminate potential (CHIP) i
222                                              Clonal hematopoiesis of indeterminate potential (CHIP) m
223                                              Clonal hematopoiesis of indeterminate potential (CHIP) o
224                                              Clonal hematopoiesis of indeterminate potential (CHIP) p
225                                              Clonal hematopoiesis of indeterminate potential (CHIP) r
226                                              Clonal hematopoiesis of indeterminate potential (CHIP) r
227 lthough the cause of these t-MNs is unknown, clonal hematopoiesis of indeterminate potential (CHIP) v
228                                              Clonal hematopoiesis of indeterminate potential (CHIP) w
229             In patients with CKD, non-DNMT3A clonal hematopoiesis of indeterminate potential (CHIP) w
230 d dysplastic hematopoiesis can be considered clonal hematopoiesis of indeterminate potential (CHIP),
231                                  Age-related clonal hematopoiesis of indeterminate potential (CHIP),
232 logous process happens in a condition called clonal hematopoiesis of indeterminate potential (CHIP),
233 ns in hematopoietic cells, frequently called clonal hematopoiesis of indeterminate potential (CHIP),
234                                              Clonal hematopoiesis of indeterminate potential (CHIP),
235                                              Clonal hematopoiesis of indeterminate potential (CHIP),
236                                              Clonal hematopoiesis of indeterminate potential (CHIP),
237                                              Clonal hematopoiesis of indeterminate potential (CHIP),
238                                              Clonal hematopoiesis of indeterminate potential (CHIP),
239                                              Clonal hematopoiesis of indeterminate potential (CHIP),
240                                              Clonal hematopoiesis of indeterminate potential (CHIP),
241                                              Clonal hematopoiesis of indeterminate potential (CHIP),
242                                              Clonal hematopoiesis of indeterminate potential (CHIP),
243            Here we explore these patterns in clonal hematopoiesis of indeterminate potential (CHIP),
244                                              Clonal hematopoiesis of indeterminate potential (CHIP),
245                      This phenomenon, termed clonal hematopoiesis of indeterminate potential (CHIP),
246                                              Clonal hematopoiesis of indeterminate potential (CHIP),
247 ith increased inflammatory responsiveness is clonal hematopoiesis of indeterminate potential (CHIP).
248 -lived trained immunity and the emergence of clonal hematopoiesis of indeterminate potential (CHIP).
249 iovascular risk factor has recently emerged: clonal hematopoiesis of indeterminate potential (CHIP).
250 tion sequencing (NGS) discovered age-related clonal hematopoiesis of indeterminate potential (CHIP).
251  critical as underscored by the incidence of clonal hematopoiesis of indeterminate potential associat
252 unotherapy outcomes to account for potential clonal hematopoiesis of indeterminate potential contamin
253 with a focus on the prevalence and impact of clonal hematopoiesis of indeterminate potential in patie
254                                              Clonal hematopoiesis of indeterminate potential is the p
255            Among individuals with JAK2 V617F clonal hematopoiesis of indeterminate potential or mCAs
256  In an adenine-induced CKD mouse model, Tet2-clonal hematopoiesis of indeterminate potential was link
257 es describe the emergence and prevalence of "clonal hematopoiesis of indeterminate potential" in aged
258 associated with hyperinflammatory responses (clonal hematopoiesis of indeterminate potential, CHIP),
259 stic boundaries between MDS, MDS/MPNs, sAML, clonal hematopoiesis of indeterminate potential, clonal
260 , acquired somatic mutations associated with clonal hematopoiesis of indeterminate potential, leukocy
261                      In individuals carrying clonal hematopoiesis of indeterminate potential, myocard
262 ave been characterized as frequent events in clonal hematopoiesis of indeterminate potential, suggest
263 atients without MDS/AML also had evidence of clonal hematopoiesis of indeterminate potential-related
264  had T-cell clonality, and 8 of 12 (67%) had clonal hematopoiesis of indeterminate potential.
265 ng individuals with idiopathic cytopenias or clonal hematopoiesis of undetermined significance, the i
266 nt somatic genetic rescue (SGR) resulting in clonal hematopoiesis, of which 95% was maladaptive (mono
267              Future studies on the effect of clonal hematopoiesis on the HIV reservoir and non-AIDS-r
268  in hematopoietic stem and progenitor cells (clonal hematopoiesis or CH) are associated with advanced
269 e is often preceded by a premalignant state (clonal hematopoiesis or myelodysplastic syndrome).
270 hieve AML cure and the impact of preleukemic clonal hematopoiesis persistence in predisposing to seco
271  malignancy consistent with the concept that clonal hematopoiesis precedes stem cell malignancy.
272 ously illuminates the clonal architecture of clonal hematopoiesis/preleukemic and leukemic cells surv
273  a cross-sectional cohort study, we compared clonal hematopoiesis prevalence in PWH on stable antiret
274 ction, not drift, is the major force shaping clonal hematopoiesis, provide bounds on the number of he
275                                              Clonal hematopoiesis provides a glimpse into the process
276                                              Clonal hematopoiesis-related genetic alterations were id
277 herosclerosis is a cause or a consequence of clonal hematopoiesis remains a matter of debate.
278        These patients have BCR-ABL1-positive clonal hematopoiesis resembling a chronic myeloid leukem
279                                              Clonal hematopoiesis results from enhanced fitness of a
280                                              Clonal hematopoiesis results from somatic mutations in h
281     In contrast to mutations associated with clonal hematopoiesis (such as Tet2 deletion), the leukem
282 ors, a phenomenon we term tumor-infiltrating clonal hematopoiesis (TI-CH).
283  Here, we will review recent studies linking clonal hematopoiesis to altered immune function, inflamm
284 s drives disease evolution from asymptomatic clonal hematopoiesis to frank MDS, and, ultimately, to s
285     Factors that control the conversion from clonal hematopoiesis to MPN disease include inherited pr
286 d across a phenotypic continuum ranging from clonal hematopoiesis to myelodysplastic syndrome (MDS) a
287 ancies exist on a spectrum from asymptomatic clonal hematopoiesis to overt leukemia and exhibit subst
288 re, we developed ArCH, an Artifact filtering Clonal Hematopoiesis variant calling pipeline for detect
289 ation pattern (XIP) was 20% (21/104), and of clonal hematopoiesis was 3% (3/104).
290                                              Clonal hematopoiesis was a strong risk factor for subseq
291                            ECD patients with clonal hematopoiesis were more likely to be older (P < .
292  screened included 40 regions known to drive clonal hematopoiesis when mutated and 64 novel candidate
293 al alterations (mCAs) represent two forms of clonal hematopoiesis where clones bearing expanded somat
294 rom normal, healthy elderly individuals with clonal hematopoiesis who are at increased risk of subseq
295 f ctDNA dynamics in EAC, taking into account clonal hematopoiesis with indeterminate potential (CHIP)
296                 Emerging data also associate clonal hematopoiesis with other nonhematologic diseases.
297 n morphologic remission may continue to have clonal hematopoiesis with populations closely related to
298                                              Clonal hematopoiesis with somatic mutations is readily d
299                                              Clonal hematopoiesis with somatic mutations was observed
300            Assays that could reliably detect clonal hematopoiesis would therefore be extremely valuab

 
Page Top